Onconetix, Inc. (ONCO), Monday announced that new clinical data from a study of its prostate cancer diagnostic test, Proclarix, was presented at the 2025 European Association of Urology or EAU congress, demonstrating the strong clinical performance of Proclarix in a Danish cohort.
In this study, Proclarix was evaluated in 808 patients with suspected prostate cancer, including a challenging subpopulation of 371 patients with enlarged prostates.
The results showed that Proclarix significantly reduced the number of unnecessary biopsies by identifying patients with a low probability of clinically significant cancer.
In this subpopulation, Proclarix achieved a 5 percent or less probability of clinically significant cancer, outperforming other diagnostic tools such as %fPSA and the ERSPC risk calculator.
The clinical performance of Proclarix was further validated in a larger group of 654 patients, achieving a sensitivity of 96 percent and significantly higher specificity compared to %fPSA and the ERSPC risk calculator.
Proclarix is an in vitro diagnostic test that combines biomarker detection with a proprietary algorithm to assess a patient's risk of clinically significant prostate cancer.
It is CE-certified under the In Vitro Diagnostic Regulation or IVDR and is included in both European and American guidelines for prostate cancer diagnosis.
Onconetix plans to market Proclarix as a lab-developed test or LDT in the U.S. through a license agreement with Labcorp.
Currently, ONCO is trading at $0.12 down by 3.42 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.